Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in ...

Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to ...

By adjusting the fat levels in mRNA-based drugs, researchers have found a way to bypass the liver and go straight to the ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ...

Explore how Moderna's (MRNA) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Currently, the most widely used vaccine against TB is the Bacillus Calmette-Guérin (BCG). Developed in 1921, the vaccine ...

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Germans Trias i Pujol Research Institute (IGTP ...

A new mRNA vaccine against tuberculosis (TB) is showing favorable results in preclinical trials. With only one currently ...